USD
GBP 
CNY 
EUR 
INR 
JPY 
MYR 
ZAR 
KRW 
THB 
Launch of Promising Late-stage Anti-hypertensive Drugs to Drive Growth of Branded ACS Therapeutics
20-May-2015
Global
Market Research
MB06-01-00-00-00
LS00109-GL-MR_16950
This research service offers an assessment for marketed and pipeline products for the global ACS therapeutics market. Segmentation by drug class is provided along with additional supporting information such as clinical trial timelines and results, historical and projected launch timelines, and epidemiology. The marketed and pipeline products are broadly segmented into anti-platelet therapeutics, anti-hypertensives and cholesterol lowering drugs, anti-thrombins, and others. Other upcoming therapies include anti-inflammatories. The forecast period is 2015–2025.
Executive Summary—Key Findings
Executive Summary—Key Findings (continued)
Key Trends
Companies to Watch
Methodology and Scope
Market Overview—Introduction
Market Overview—Epidemiology
Market Overview—Epidemiology (continued)
Market Overview—Epidemiology (continued)
Physicians Treatment Guidelines
Physicians Treatment Guidelines (continued)
Physicians Treatment Guidelines (continued)
Physicians Treatment Guidelines (continued)
Market Size
Market Size—Segmentation
Market Forecast
Market Segmentation
Competitive Landscape Overview
Competitive Landscape—Marketed and Pipeline Products
Marketed Products—Anti-platelet Therapy
Pipeline Products—Anti-platelet Therapy
Marketed Products—Anti-thrombin Therapy
Marketed Products—Anti-thrombin Therapy (continued)
Pipeline Products—Anti-thrombin Therapy
Marketed Products—Anti-hypertensives & Cholesterol Lowering Drugs
Marketed Products—Anti-hypertensives & Cholesterol Lowering Drugs (continued)
Pipeline Products—Anti-hypertensives & Cholesterol Lowering Drugs
Pipeline Products—Others
Product Launch Timeline
Patent Expirations
ACS Therapeutics—Major Ongoing/Recently Completed Clinical Trials
ACS Therapeutics—Major Ongoing/Recently Completed Clinical Trials (continued)
Summary of Key Products to Watch
Product Dashboard: Plavix (clopidogrel)—Bristol-Myers Squibb
Product Dashboard: Brilinta (ticagrelor)—The Medicines Company
Product Dashboard: Angiomax—The Medicines Company
Product Dashboard: Zocor (simvastatin)—Merck
Product Dashboard: Xarelto (rivaroxaban)—Bayer
Product Dashboard: Alirocumab (RGN727)—Sanofi & Regeneron
Product Dashboard: Evolocumab (Repatha)—Amgen
Product Dashboard: Evacetrapib—Eli Lilly & Company
Product Dashboard: Losmapimod—GSK
Conclusions
Legal Disclaimer
Decision Support Database
Decision Support Database (continued)
Decision Support Database (continued)
Decision Support Database (continued)
The Frost & Sullivan Story
Value Proposition—Future of Your Company & Career
Global Perspective
Industry Convergence
360º Research Perspective
Implementation Excellence
Our Blue Ocean Strategy
Speak directly with our analytics experts for tailored recommendations.
Recent related Life Sciences research
13 Jan 2025 | Global | Market Outlook
Top 6 Growth Opportunities for the Digital Health Industry, 2025
Driven by digital advancements, the healthcare industry is transforming rapidly. Current trends and challenges create constant change, and industry stakeholders must adapt to remain attractive, competitive, and unique as robust organizations. Each year, competitors must gain a fresh, comprehensive v...
17 Dec 2024 | Global | Market Research
Cybersecurity in Healthcare, United States, 2024
Healthcare is the industry most affected by cyberattacks, which have targets like hospitals, healthcare organizations, patient databases, and connected devices. These attacks not only destabilize healthcare systems but also threaten care delivery and patient safety. The global healthcare infrastruct...
12 Dec 2024 | Global | Market Outlook
Top 6 Growth Opportunities for Clinical Diagnostics, Global, 2025
Accounting for 2%-3% of total healthcare expenditure and influencing 70% of clinical decision-making, diagnostics is the silent champion supporting all stages of precision health, including risk stratification, screening, early diagnosis, prognosis, monitoring, and relapse. The discovery and trans...
05 Dec 2024 | Global | Frost Radar
Frost Radar™: Enterprise Conversational AI in Healthcare, 2024
This Frost Radar™ benchmarks the companies and their solutions that allow healthcare payers and providers to create next-generation virtual assistants. Conversational AI is primarily used to streamline patient and provider processes and interactions across the care continuum—the pre-care, at-care, a...
27 Nov 2024 | Global | Market Research
Generative AI in Payer and Provider IT Transformation, Global, 2024-2029
The healthcare payer and provider industry is gradually adopting generative artificial intelligence (Gen AI) solutions across its value chain. Almost all organizations have shown an intent to implement Gen AI-based solutions in their products or processes, with a few already embarking on this journe...
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
| Deliverable Type | Market Research |
|---|---|
| No Index | No |
| Podcast | No |
| Author | Sriram Radhakrishnan |
| WIP Number | MB06-01-00-00-00 |
| Is Prebook | No |
A Competitive Analysis of the Global Acute Coronary Syndrome (ACS) Therapeutics Market
$3,950.00
Special Price $2,962.50 save 25 %